Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | BHMT | Q93088 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | MVD | P53602 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14157523 | 0.98 | CYP2D6 (0.48) | CYP2D6HIF1AHSD17B10GMNNTP53 | |
| SCHEMBL16713418 | 0.86 | GMNN (0.55) | CYP2D6HIF1AHSD17B10GMNNTP53 | |
| SCHEMBL5277669 | 0.81 | ALDH1A1 (0.39) | HSD17B10GMNNTP53POLBMAPT | |
| SCHEMBL9525474 | 0.81 | HTR1A (0.36) | HSD17B10GMNNTP53POLBMAPT | |
| SCHEMBL20411535 | 0.81 | CES2 (0.48) | HSD17B10GMNNTP53POLBMAPT | |
| SCHEMBL16727727 | 0.80 | GMNN (0.48) | CYP2D6HIF1AHSD17B10GMNNTP53 | |
| SCHEMBL10408722 | 0.79 | LMNA (0.64) | HSD17B10BHMTALDH1A1CYP2C19TSHR | |
| SCHEMBL890300 | 0.77 | MAPT (0.50) | CYP2D6HIF1AHSD17B10GMNNTP53 | |
| SCHEMBL1313188 | 0.76 | CYP2D6 (0.73) | CYP2D6HIF1AHSD17B10GMNNTP53 | |
| SCHEMBL677698 | 0.76 | HTR1A (0.41) | BHMTHTR1ADRD2HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003066-A | Ionizable cation lipid for RNA delivery | 阿克丘勒斯治疗公司 | 2019-07-12 | — | — | CN | claimed |
| US-12533410-B2 | Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2026-01-27 | — | — | US | disclosed |
| US-RE50681-E1 | Ionizable cationic lipid for RNA delivery | ARCTURUS THERAPEUTICS, INC (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250304532-A1 | METHOD OF SYNTHESIS OF AN IONIZABLE CATIONIC LIPID | ARCTURUS THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| US-12286395-B2 | Method of synthesis of an ionizable cationic lipid | ARCTURUS THERAPEUTICS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| EP-3071547-B1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20230390389-A1 | Nucleic Acid Vaccine Composition Comprising a Lipid Formulation, and Method of Increasing the Potency of Nucleic Acid Vaccines | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2023-12-07 | — | — | US | disclosed |
| EP-3221293-B1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS INC (US) | 2023-03-01 | — | — | EP | disclosed |
| US-RE49233-E1 | Ionizable cationic lipid for RNA delivery | ARCTURUS THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-RE49233-E1 | Ionizable cationic lipid for RNA delivery | ARCTURUS THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| WO-2012170952-A9 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-02-21 | — | — | WO | disclosed |
| WO-2012170952-A9 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-02-21 | — | — | WO | disclosed |
| US-20130022665-A1 | CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORPORATION (JP) | 2013-01-24 | — | — | US | disclosed |
| US-20130022665-A1 | CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORPORATION (JP) | 2013-01-24 | — | — | US | disclosed |
| US-20130022665-A1 | CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORPORATION (JP) | 2013-01-24 | — | — | US | disclosed |
| WO-2012170952-A2 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012170952-A2 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2012-12-13 | — | — | WO | disclosed |
| EP-0226896-B1 | LANKACIDIN DERIVATIVES AND PRODUCTION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 1993-09-15 | — | — | EP | disclosed |
| US-4914206-A | ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-04-03 | — | — | US | disclosed |
| EP-0226896-A2 | Lankacidin derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390389-A1 | Nucleic Acid Vaccine Composition Comprising a Lipid Formulation, and Method of Increasing the Potency of Nucleic Acid Vaccines | LPCAT1, LPCAT3, LCAT | CYP2D6 4059/4885HIF1A 4582/4885HSD17B10 767/4885 |
| US-20130022665-A1 | CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | SGMS1, SGMS2, S1PR3 | CYP2D6 2626/4885HIF1A 1511/4885HSD17B10 1471/4885 |
| US-12533410-B2 | Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines | LPCAT1, CETP, LPCAT3 | CYP2D6 3856/4885HIF1A 4479/4885HSD17B10 656/4885 |
| US-12286395-B2 | Method of synthesis of an ionizable cationic lipid | SGMS1, SGMS2, LIPA | CYP2D6 1222/4885HIF1A 3610/4885HSD17B10 102/4885 |
| US-20250304532-A1 | METHOD OF SYNTHESIS OF AN IONIZABLE CATIONIC LIPID | SGMS1, SGMS2, LIPA | CYP2D6 1222/4885HIF1A 3610/4885HSD17B10 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.